Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products. Tatva Chintan expects a 20% to 25% compounded annual growth rate (CAGR) in revenue over the next 3 to 4 years.
From Tatva Chintan Pharma Chem Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products.
- Q1 FY27 saw a 43% year-on-year revenue growth and 25% sequential increase, indicating strong momentum.
- Phase Transfer Catalysts and Structure Directing Agents (SDA) segments show robust demand expansion, supported by Euro 7 implementation and wider market acceptance.
- Electrolyte Salts segment is expected to contribute around 10% of revenue in FY27, with gradual ramp-up driven by hybrid vehicle battery commercialization post-2026.
- The company plans a greenfield capacity expansion to boost future revenue potential by INR300 crores at peak utilization.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Tatva Chintan has a planned greenfield capex of INR 200 crores for FY27 aimed at scaling up R&D-ready products and catering to domestic demand.
- The new multiproduct facility will support pharma and agro intermediates, electrolytes, SDA, and other sectors, with an expected peak revenue of around INR 300 crores.
- This facility is planned to be operational within 18 to 21 months, addressing expected growth beyond INR 800-850 crores revenue.
- The company is also focusing on debottlenecking and continuous flow chemistry upgrades in existing plants to optimize capacity.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Tatva Chintan does not maintain a traditional order book with confirmed orders.
- Orders are generally received and fulfilled on a quarter-on-quarter basis.
- Customer demand is described as very visible and highly clear.
- There is no specific order book in hand currently, as per the management's statement.
2 more points management made on order book & pipeline
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹134 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
- Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
- Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…
- Chemfab Alkalis Ltd (Q1 FY27)
Consolidated Q1FY27 Revenue from Operations:** ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). Key concall takeaways from Chemfab Alkalis Ltd's Q1…
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q1 FY27 results?
Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products. Tatva Chintan expects a 20% to 25% compounded annual growth rate (CAGR) in revenue over the next 3 to 4 years.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 79.0 with a market cap of ₹4,141 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
Tatva Chintan has a planned greenfield capex of INR 200 crores for FY27 aimed at scaling up R&D-ready products and catering to domestic demand.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.